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Post-ischemic reperfusion injury is mediated by infiltration 
and activation of circulating inflammatory cell subsets 
(i.e., neutrophils) that early entered the area-at-risk and 
release proteases and reactive oxygen species (ROS) (1-3). A 
recent study demonstrated that during recovery neutrophil 
infiltration might be protective, thus favoring a proper scar 
formation and potentially preventing negative left ventricle 
remodeling (4). Given this pathophysiological complexity, 
some selective drugs targeting these cells failed to induce 
a clear benefit on mortality and post-ischemic heart failure 
development in experimental models (2,5). Treatment 
schedule and safety (i.e., risk of immunosuppression) 
were suggested as the key limiting issues, potentially 
weakening the relevance of pre-clinical studies. However, 
despite a promising pilot study (6), patients with acute ST-
segment elevation myocardial infarction (STEMI), did 
not benefit of the acute administration of cyclosporine 
(an immunosuppressive drug) on post-infarction clinical 
outcomes (7,8). Therefore, evidence from both basic and 
clinical research raised some concerns on therapeutic 
approaches inhibiting inflammation in all phases of post-
ischemic reperfusion. A clear need of more selective 
treatments transiently abrogating inflammation might be 
more effective and safe. 
Since decades, therapeutic hypothermia (TH) is 
empirically considered as a useful physical approach 
abrogating inflammation and reducing cellular metabolism 
of ischemic cells (9).
This approach was first supposed to be neuroprotective 
in survivors of cardiac arrest (10) and then, investigated 
to reduce cardiac injury (11). More recently, a systematic 
review and meta-analysis of randomized controlled trials 
(RCTs) investigated if TH might significantly reduce major 
adverse cardiovascular events (MACEs) as compared to 
controls in patients with STEMI. 
Villablanca and co-workers evaluated the clinical 
efficacy of this approach not only on MACEs (primary 
end point), but also on secondary end points, such as all-
cause mortality, new myocardial infarction, heart failure/
pulmonary oedema and infarct size (12). Finally, safety 
endpoints (i.e., all-bleeding, ventricular tachycardia and 
bradycardias) were also assessed. In the meta-analysis, 819 
patients from six RCTs that met criteria (the study was a 
RCT, age >18, diagnosis of STEMI, assessment of MACEs 
and TH administered in the setting of acute disease) were 
included. 
The meta-analysis failed to show a clear clinical benefit 
of TH on post-STEMI outcomes. Only a sub-analysis of 
4 RCTs that specified site of infarction (13-16) suggested 
that patients with anterior wall infarct had a reduction 
in infarct size when submitted to TH as compared to 
controls. Despite preliminary, since this minor result 
came from only four RCTs, the article by Villablanca 
and co-workers suggests that TH might be useful in 
a selected population with cardiac arrest or some sub-
groups of patients with STEMI. These results might be 
also explained by the fact that, differently from animal 
models of myocardial ischemia/reperfusion in which each 
1 ℃ lowering of blood temperature cause a reduction in 
infarct size of 10% (17), the majority of STEMI patients 
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in these RTCs did not reach the target temperature (12). 
These results were potentially influenced by the method to 
induce HT that was different in the RCTs [five RCTs used 
endovascular inferior vena cava (IVC) catheters and one a 
peritoneal catheter] (12). The use of an IVC catheter was 
previously associated with the induction of a slow HT as 
compared to the infusion of chilled intravenous fluid, thus 
unappropriated for the time PCI procedure (18). On the 
other hand, a more rapid heart cooling was reported by 
the peritoneal HT (19). However, the target temperature 
by standard TH protocol might be hard to be reached also 
when using this second device. 
This meta-analysis did not apparently raise major 
concerns on safety. Although the safety end points were 
not recorded in all six RCTs at the same time, TH induced 
similar adverse events (i.e., all-bleeding, ventricular 
arrhythmias and bradycardia) as compared to controls. We 
might speculate that future TH RCTs in selected STEMI 
population might not risk to be limited by safety issues.
As part ia l ly  acknowledged by the authors ,  the 
limited sample size for efficacy suggests that a meta-
analysis in the next five years might be reasonable. We 
believe that such study should take into the account of 
standardized definitions of MACEs, hypothermia and 
target temperatures. The meta-analysis by Villablanca 
and colleagues has to be considered as preliminary result 
that requires additional confirmation. In fact, we believe 
that reduction in ischemia/reperfusion injury is critical to 
improve sequelae after effective revascularization in patients 
with STEMI. A better pathophysiological knowledge of 
inflammatory processes related to reperfusion injury might 
help to develop more efficient and timely treatments. 
TH was already beneficial in animal models of ischemia/
reperfusion (17). However, as it often happens, the 
translation of basic research results into human disease 
might have some difficulties. As identified by Bolli and 
co-workers, multiple barriers are interposed between the 
animal model and the patient (20). The most relevant 
clinical barriers are comorbidities, pharmacological 
ongoing treatments, population bias and the inability to 
identify and pre-treat patient with STEMI. TH remains 
a promising strategy in patients with STEMI. Additional 
RCTs are needed to conclude and potentially provide 
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